Medaviate

Dr. Manish Singhal

Experience: 21 years overall

Education: MBBS, DM (oncology), MD (general medicine)

Specializations: Medical Oncologist

Department: Medical Oncology

Registration: 31294 Delhi Medical Council, 2006

Hospital: Indraprastha Apollo Hospital

INTRODUCTION:

Dr. Manish Singhal is a medical oncologist in Sarita Vihar, Delhi, and has over 21 years of experience in the field of oncology. He got his MBBS degree from the University of Mumbai, Mumbai, in 2002, MD: General Medicine from MDU, Rohtak, in 2006, and DM: Oncology from AIIMS, New Delhi, in 2010

Experience

  • Medical Oncologist at Indraprastha Apollo Hospital.

Education

  • MBBS – University of Mumbai, Mumbai, 2002.
  • MD – General Medicine, MDU, Rohtak, 2006.
  • DM – Oncology – All India Institute of Medical Sciences, New Delhi, 2010.

Awards and Recognitions

  • Awarded with the Best Exam Award for ESMO (European Society of Medical Oncology) 2013 exam to receive the best grades worldwide.
  • Awarded best doctor for 2014 and 2015 during my tenure for receiving the highest outstanding patient reviews and feedback.
  • Executive Committee member (ISMPO).
  • Joint Secretary (NCR) Oncology Forum.

Membership

  • Indian Academy of Clinical Medicine.
  • Association of Physicians of India.
  • Indian Cooperative Oncology Network.
  • Indian Society of Medical and Pediatric Oncology
  • Oncology Forum.
  • European Society of Medical Oncology.
  • American society of clinical oncology.

Projects and research

  • Quantitative estimation of bcr-abl transcripts to see molecular remission status in patients with chronic myeloid leukemia (2008–2010).
  • Iniparib in TNBC: multinational phase 3 study, 2010–2012, Co-PI.
  • Relooking at the need for disclosure: The Play of Knowing and Not Knowing in the Terminally Ill, MPhil Thesis (Ambedkar University), Dr. Meghna, 2014, Co-Guide.
  • TDM-1 in breast cancer: post-taxane and trastuzumab, 2016; PI (enrolled 5 patients, ongoing).
  • Ancers-1: Canscript in Solid Organ Malignancies, 2017-PI (enrolled 8 patients, ongoing)
  • Povidone-iodine RCT (multinational) for chemotherapy-induced paronychia, 2017; PI (yet to start enrollment, EC-cleared).
  • Zytiga in prostate cancer, phase IV, 2016–17, PI (no patient enrolled, competition with cheaper generics).
  • Ninetidanib in NSCLC, phase IV, 2017-PI.
  • Atezolizumab with Paclitaxel: International Study Roche Impassion 131., 2018 (PI).
  • Ipatasertib with Paclitaxel (International Study Roche, 2019).
  • Ezetimibe as an adjunct to atorvastatin in patients with dyslipidemia, 2004–2006, published in the Indian Heart Journal.
  • Prognostic Value of Plasma High Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction, 2005–2007, published in the Indian Heart Journal.